Does Repatha Worsen Myopathy?
No, Repatha (evolocumab) does not worsen myopathy and is actually associated with similar or lower rates of muscle-related adverse events compared to placebo or standard statin therapy.
Evidence from FDA Drug Label and Clinical Trials
According to the FDA-approved prescribing information, myalgia occurred in 4.0% of Repatha-treated patients versus 3.0% of placebo-treated patients in the 52-week controlled trial 1. Importantly, myalgia was the most common adverse reaction leading to discontinuation, but this occurred in only 0.3% of Repatha patients versus 0% on placebo 1. This represents a minimal absolute difference that is not clinically concerning.
Large-Scale Safety Data
The most robust safety evidence comes from:
Pooled analysis of over 6,000 patients: Muscle-related adverse events were similar between evolocumab and control groups across 12 phase 2/3 trials and open-label extension studies 2
FOURIER trial (27,564 patients): The landmark cardiovascular outcomes trial showed no significant difference in adverse events between evolocumab and placebo, with the exception of injection-site reactions 3
Network meta-analysis (2024): Among PCSK9 inhibitors, evolocumab showed the best results for both new muscle symptom events and creatine kinase >3× upper limit of normal 4
Key Clinical Context
Evolocumab does not cause or worsen myopathy because:
Different mechanism of action: Unlike statins that inhibit cholesterol synthesis in muscle tissue, evolocumab works by binding PCSK9 in the bloodstream, increasing hepatic LDL receptor recycling 5
No muscle tissue penetration: As a monoclonal antibody, evolocumab does not enter muscle cells where statin-related myopathy occurs
Lower muscle symptoms than statins: When added to maximally tolerated statin therapy, the annualized event rate for muscle symptoms was actually 4.7% with PCSK9 inhibitors versus 8.5% with standard of care 6
Important Caveats
Myalgia as a symptom (muscle pain without elevated CK) can occur at similar rates to placebo, likely representing background musculoskeletal complaints in this population 1
True myopathy (muscle symptoms with CK elevation) and rhabdomyolysis are not increased with evolocumab 2
The 2022 ACC Expert Consensus specifically notes that evolocumab's adverse effects in ASCVD patients include nasopharyngitis and upper respiratory infections—not myopathy 5
Clinical Recommendation
Repatha is safe to use in patients with statin-associated muscle symptoms and does not worsen myopathy. In fact, it represents an excellent alternative for patients who cannot tolerate adequate statin doses due to muscle-related side effects. The drug can be confidently prescribed without concern for exacerbating or causing myopathy, as the mechanism of action does not involve muscle tissue and extensive clinical trial data demonstrate no increased risk 5, 1, 2, 4.